首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1493626

肺癌诊断市场 - 全球产业规模、份额、趋势、机会和预测，按类型、地区和竞争测试划分，2019-2029F

Lung Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Test By Region and Competition, 2019-2029F

出版日期: 2024年05月15日 | 出版商:

TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年全球肺癌诊断市场估值为14.1 亿美元，预计到2029 年预测期内将稳定成长，复合年增长率为6.86%。重要的领域，致力于检测和诊断肺癌，这种疾病因其高死亡率和盛行率而受到全球关注。肺癌诊断包括各种旨在早期识别和监测的工具、技术和服务，最终改善患者的治疗结果。

市场概况
预测期	2025-2029
2023 年市场规模	14.1亿美元
2029 年市场规模	20.8亿美元
2024-2029 年复合年增长率	6.86%
成长最快的细分市场	分子测试
最大的市场	北美洲

肺癌发生率持续居高不下，很大程度上归因于吸烟、环境暴露和遗传倾向等因素，这推动了对准确、高效诊断方法的需求。鑑于早期检测有可能提高治疗成功率和长期存活率，人们越来越重视早期检测。各种诊断方式激增，包括 X 光、CT 扫描和 PET 扫描等影像技术，以及痰细胞学和 PCR 和新一代定序等先进分子测试。

液体活检技术已经取得了重大进展，提供了检测血液或其他体液中与癌症相关的突变和生物标记的非侵入性方法。这些创新支持向个人化医疗的转变，实现基于个别基因谱的客製化治疗策略和标靶治疗。研发投资的增加、製药公司和诊断提供者之间的合作以及对患者意识和教育的加强努力也塑造了市场。

COVID-19 大流行凸显了呼吸系统健康的重要性，增强了肺癌诊断的重要性。随着世界各地的医疗保健系统应对疫情带来的挑战，人们重新关注增强对包括肺癌在内的呼吸道疾病的诊断能力。这促进了诊断技术的进一步创新和投资，使全球肺癌诊断市场处于医疗保健进步的前沿。

主要市场驱动因素

肺癌发生率上升

越来越重视早期检测

成像技术的进步

主要市场挑战

晚期诊断

诊断费用

主要市场趋势

液体切片的兴起

分子诊断与精准医学

细分市场洞察

类型洞察

测试见解

区域洞察

Global Lung Cancer Diagnostics Market was valued at USD 1.41 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.86% through 2029. The Global Lung Cancer Diagnostics Market is a dynamic and crucial sector within the broader healthcare industry, dedicated to detecting and diagnosing lung cancer, a disease of significant global concern due to its high mortality rates and prevalence. Lung cancer diagnostics encompass a diverse range of tools, technologies, and services aimed at early identification and monitoring, ultimately improving patient outcomes.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.41 Billion
Market Size 2029	USD 2.08 Billion
CAGR 2024-2029	6.86%
Fastest Growing Segment	Molecular Test
Largest Market	North America

The persistently high incidence of lung cancer, largely attributable to factors like smoking, environmental exposures, and genetic predisposition, drives the demand for accurate and efficient diagnostic methods. Emphasis on early detection has grown, given its potential to enhance treatment success and long-term survival rates. Various diagnostic modalities have proliferated, including imaging techniques like X-rays, CT scans, and PET scans, as well as sputum cytology and advanced molecular tests such as PCR and next-generation sequencing.

Significant advancements in liquid biopsy technologies have emerged, offering non-invasive means of detecting cancer-related mutations and biomarkers in blood or other bodily fluids. These innovations support the shift towards personalized medicine, enabling tailored treatment strategies and targeted therapies based on individual genetic profiles. The market is also shaped by increased investments in research and development, collaborations between pharmaceutical firms and diagnostic providers, and heightened efforts towards patient awareness and education.

The COVID-19 pandemic has underscored the importance of respiratory health, amplifying the significance of lung cancer diagnostics. As healthcare systems worldwide navigate the challenges posed by the pandemic, there is a renewed focus on enhancing diagnostic capabilities for respiratory diseases, including lung cancer. This has prompted further innovation and investment in diagnostic technologies, positioning the Global Lung Cancer Diagnostics Market at the forefront of healthcare advancement.

Key Market Drivers

Rising Incidence of Lung Cancer

The rising incidence of lung cancer is a significant driver behind the burgeoning Global Lung Cancer Diagnostics Market. Lung cancer remains a formidable global health challenge, primarily fueled by factors such as smoking, environmental pollutants, and genetic predisposition. This increase in the number of individuals afflicted by the disease necessitates more advanced and efficient diagnostic tools and methods, further propelling the growth of the diagnostic market. Lung cancer is one of the most commonly diagnosed cancers worldwide, and its incidence has been steadily increasing over the years. This upsurge is due, in part, to the persistence of smoking habits in certain populations and the emergence of new environmental carcinogens. In addition, genetic factors play a crucial role in determining an individual's susceptibility to lung cancer, and these genetic predispositions continue to contribute to the rising incidence.

The implications of this growing incidence of lung cancer are twofold. First, it places an increasing burden on healthcare systems, necessitating more effective and efficient diagnostic approaches to identify cases early, when treatment options are often more successful. Second, the demand for advanced diagnostics, including imaging techniques, molecular testing, and liquid biopsies, is escalating to ensure accurate and timely diagnosis. This surge in demand is shaping the diagnostic market, leading to continuous innovations and the development of cutting-edge technologies aimed at improving the early detection and monitoring of lung cancer.

Growing Emphasis on Early Detection

The Global Lung Cancer Diagnostics Market is experiencing significant growth due to a pronounced emphasis on early detection. Early diagnosis is recognized as a pivotal factor in improving the prognosis and outcomes for lung cancer patients, and as a result, healthcare systems, professionals, and patients are increasingly focused on timely identification of this deadly disease.

Early detection holds the key to better survival rates and a wider range of treatment options. In the context of lung cancer, when the disease is caught at an early stage, patients often have a better chance of curative treatment, including surgery, radiation therapy, and targeted therapies. In contrast, late-stage diagnoses tend to be associated with more limited treatment options and poorer survival rates. This fundamental difference underscores the critical role that early detection plays in the management of lung cancer. To facilitate early detection, there has been a concerted effort to promote awareness and education about the risk factors and symptoms associated with lung cancer. Smoking cessation campaigns, public health initiatives, and educational programs are aimed at informing individuals about the importance of regular screenings, especially for those with a history of smoking or other risk factors. Such initiatives have encouraged individuals to seek out diagnostic evaluations at the earliest signs of potential lung cancer symptoms, such as persistent cough, chest pain, or unexplained weight loss.

Technological advancements in diagnostic tools and modalities have further facilitated early detection. Imaging technologies, like low dose computed tomography (LDCT) scans, have proven to be highly effective in identifying lung cancer at its earliest stages. Molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have allowed for the detection of specific genetic mutations and alterations in lung cancer cells, providing clinicians with vital information for early and accurate diagnosis.

Advancements in Imaging Technologies

Advancements in imaging technologies are playing a pivotal role in boosting the Global Lung Cancer Diagnostics Market. These cutting-edge diagnostic tools are transforming the landscape of lung cancer diagnosis, enabling earlier detection and more precise assessments of the disease, ultimately improving patient outcomes. Imaging technologies, including X-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, have witnessed remarkable progress in recent years. These innovations have enhanced their capabilities in visualizing lung tumors, assessing the extent of cancer spread, and monitoring the disease's progression. Such advancements in imaging are reshaping the lung cancer diagnostics market in several ways.

CT scans, in particular, have evolved to offer higher image resolution, reduced radiation exposure, and the ability to capture images at a faster pace, resulting in more accurate and detailed assessments. This not only aids in the early identification of lung cancer but also supports precise staging, which is crucial for determining the most appropriate treatment strategy. The integration of artificial intelligence (AI) and machine learning into these imaging technologies has revolutionized their diagnostic potential. AI algorithms can quickly analyze vast sets of imaging data to identify suspicious nodules or lesions, leading to expedited diagnoses and reducing the risk of oversight. Such AI-driven systems have demonstrated their efficiency in distinguishing between benign and malignant lung lesions, enhancing the diagnostic accuracy and reducing the rate of false positives.

Advancements in imaging technologies are facilitating the use of minimally invasive procedures, such as image-guided biopsies, which have become standard practice in the diagnosis of lung cancer. These procedures are less invasive and pose fewer risks to patients, enabling clinicians to obtain tissue samples with precision, especially in cases where the tumor's location is challenging to access.

Key Market Challenges

Late-stage Diagnoses

Late-stage diagnoses of lung cancer present a significant hindrance to the progress of the Global Lung Cancer Diagnostics Market. Despite advances in diagnostic technologies and increased awareness of the importance of early detection, many cases of lung cancer continue to be diagnosed at advanced stages, which has far-reaching implications for patient outcomes and healthcare systems. Late-stage diagnoses often result in limited treatment options and reduced survival rates. In advanced stages of lung cancer, the disease has typically spread beyond the lung, making curative treatment more challenging. Patients may require more aggressive therapies, experience a higher burden of symptoms, and face a lower chance of successful treatment outcomes. The financial burden on healthcare systems also intensifies as the cost of treating late-stage lung cancer is substantially higher than treating the disease in its earlier stages.

The primary challenge underlying late-stage diagnoses is convincing individuals to undergo regular screenings and recognize the importance of early detection. A persistent issue is the social stigma associated with lung cancer, particularly in cases where smoking is involved. This stigma can lead to hesitation in seeking medical attention, with individuals often delaying the visit to a healthcare provider until symptoms become severe. It's essential to tackle this stigma head-on by creating a supportive and non-judgmental environment for lung cancer patients and raising awareness about risk factors, which extend beyond smoking, such as exposure to environmental carcinogens. Inadequate access to healthcare services, especially for individuals in underserved areas and those lacking health insurance, can deter timely diagnoses.

Cost of Diagnostics

The cost of diagnostics remains a formidable challenge hindering the progress of the Global Lung Cancer Diagnostics Market. While advancements in diagnostic technologies have significantly improved the accuracy and effectiveness of lung cancer detection, the financial burden associated with these diagnostic procedures can act as a barrier for both patients and healthcare systems. One of the key challenges is the affordability of diagnostic tests, particularly advanced imaging techniques and molecular testing. High costs can deter individuals from seeking regular screenings, especially those at higher risk, such as smokers or those with a family history of lung cancer. In regions with limited access to affordable healthcare, these costs can be prohibitive, preventing timely diagnosis and early intervention.

Efforts to address this challenge include advocating for insurance coverage of lung cancer screenings. Ensuring that insurance plans cover the cost of screenings, particularly for individuals at high risk, can make these crucial diagnostic tools more accessible. Furthermore, policies and initiatives promoting cost-effective diagnostic methods, such as low-dose computed tomography (LDCT) scans, can help reduce the financial burden on both patients and healthcare systems. Pharmaceutical companies and diagnostic providers can also contribute by offering more affordable diagnostic solutions. Competition in the market and the development of cost-effective alternatives can drive down the overall cost of lung cancer diagnostics, making them more accessible to a broader population.

Key Market Trends

Rise of Liquid Biopsies

The rise of liquid biopsies is proving to be a transformative force in boosting the Global Lung Cancer Diagnostics Market. Liquid biopsies, which involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in bodily fluids like blood, represent a revolutionary trend in the realm of lung cancer diagnostics. This innovative approach to lung cancer diagnosis is non-invasive and provides real-time insights into the disease, making it invaluable for early detection and continuous monitoring. Liquid biopsies offer a dynamic window into the genetic makeup of cancer, enabling clinicians to detect cancer-related mutations and alterations in the bloodstream. In the context of lung cancer, this allows for the identification of specific genetic markers associated with the disease, guiding treatment decisions and providing a more personalized approach to patient care.

Liquid biopsies offer several distinct advantages over traditional tissue biopsies. They are minimally invasive, causing less discomfort to patients and reducing the risk of complications. Unlike tissue biopsies, which require surgical procedures, liquid biopsies are relatively quick and simple to perform. They also allow for repeated testing, making them ideal for monitoring disease progression and treatment efficacy over time. The trend of liquid biopsies is revolutionizing the diagnosis and management of lung cancer by offering a less burdensome and more dynamic method for assessing the disease.

Patients, especially those at high risk, are more likely to undergo these screenings, and healthcare providers can swiftly adapt treatment strategies based on real-time information. Liquid biopsies can detect the presence of minimal residual disease, helping to identify cancer recurrence earlier than traditional imaging methods. The growth of liquid biopsies is significantly contributing to the advancement of the Global Lung Cancer Diagnostics Market by expanding the range of diagnostic options available to healthcare providers.

Molecular Diagnostics and Precision Medicine

Molecular diagnostics and precision medicine are two pivotal factors significantly boosting the Global Lung Cancer Diagnostics Market. These cutting-edge approaches have fundamentally transformed the way lung cancer is diagnosed and treated, leading to more personalized and effective healthcare strategies for patients. Molecular diagnostics, involving techniques like polymerase chain reaction (PCR) and next-generation sequencing (NGS), have empowered clinicians to delve into the genetic intricacies of lung cancer. These methods enable the identification of specific genetic mutations and alterations in lung cancer cells, allowing for more accurate and targeted diagnoses. By pinpointing the precise genetic profile of an individual's cancer, clinicians can tailor treatment plans to match the unique characteristics of the disease. This not only increases the likelihood of treatment success but also minimizes potential side effects, as therapies can be chosen based on their efficacy for the specific genetic mutation present.

The integration of molecular diagnostics into lung cancer care aligns perfectly with the paradigm of precision medicine. Precision medicine takes into account an individual's genetic makeup, lifestyle, and environmental factors to develop personalized treatment plans. In the context of lung cancer, this approach has resulted in more effective and less invasive treatments. Targeted therapies, guided by the specific genetic mutations identified through molecular diagnostics, have become the cornerstone of precision medicine in lung cancer care.

Patients are experiencing better outcomes, reduced side effects, and a higher quality of life as a result. The trend of molecular diagnostics and precision medicine is not only transforming patient care but is also contributing to the growth of the Global Lung Cancer Diagnostics Market. The demand for these innovative diagnostic methods, and the therapies they inform, is driving continuous research and development in the field. Pharmaceutical companies are increasingly investing in the development of targeted therapies, and healthcare providers are integrating molecular diagnostics into their routine practice.

Segmental Insights

Type Insights

Based on the type, non-small cell lung cancer (NSCLC) emerged as the dominant segment in the lung cancer diagnostics market in 2023. NSCLC accounts for the majority of lung cancer cases, making it the more prevalent type. Approximately 80-85% of all lung cancer diagnoses are NSCLC, while small cell lung cancer (SCLC) constitutes the remaining 15-20%. The higher prevalence of NSCLC naturally results in a greater demand for diagnostic services and tools tailored to this specific form of lung cancer. Recent advancements in the treatment of NSCLC have been closely linked to diagnostic breakthroughs. The development of targeted therapies and immunotherapies, which are highly effective in certain NSCLC subtypes, underscores the importance of precise diagnostics to identify patients who will benefit the most. The evolving landscape of NSCLC therapies further emphasizes the need for advanced diagnostic methods to select the most suitable treatment options.

Test Insights

Based on the test, the imaging test emerged as the dominant segment in the global lung cancer diagnostics market in 2023. Imaging tests, particularly computed tomography (CT) scans, are the most widely utilized tests, creating high demand in the Global Lung Cancer Diagnostics Market. Imaging tests, especially low-dose CT scans, have proven to be highly effective in the early detection of lung cancer. Early diagnosis is crucial for improving patient outcomes, as it enables healthcare providers to catch the disease at a more treatable stage. The ability of CT scans to visualize lung tumors and lesions, even before symptoms manifest, makes them an essential tool for early detection. Imaging tests, particularly CT scans, are non-invasive and relatively comfortable for patients. They do not require surgical procedures or the collection of tissue samples, which can be intimidating and invasive. This non-invasive characteristic promotes higher patient compliance and encourages more individuals to undergo regular screenings.

Regional Insights

North America emerged as the dominant region in the global lung cancer diagnostics market in 2023, holding the largest market share. North America boasts some of the most advanced and comprehensive healthcare infrastructure in the world. The region is home to state-of-the-art medical facilities, well-established healthcare systems, and a high concentration of specialized diagnostic centers. This advanced infrastructure provides a strong foundation for the growth of the lung cancer diagnostics market. The North American region, particularly the United States and Canada, has a relatively high incidence of lung cancer. This elevated prevalence of the disease places a greater demand for diagnostic services and tools. As a result, there is a substantial market for lung cancer diagnostics to serve the needs of both early detection and ongoing disease management..

Key Market Players

Sanofi S.A.

Roche Diagnostics Corporation

bioMerieux SA

Qiagen N.V.

Agilent Technologies, Inc.

Thermo Fisher Scientific Inc.

AstraZeneca plc

Illumina Inc.

Johnson & Johnson

Abbott Laboratories Inc

Report Scope:

In this report, the Global Lung Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Diagnostics Market, By Type:

Small Cell Lung Cancer Non-small Cell Lung Cancer

Lung Cancer Diagnostics Market, By Test:

Imaging Test Biopsy Sputum Cytology Molecular Test Others

Lung Cancer Diagnostics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Diagnostics Market.

Available Customizations:

Global Lung Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer)
- 5.2.2. By Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2023)
5.3. Market Map
- 5.3.1. By Type
- 5.3.2. By Test
- 5.3.3. By Region

6. Asia Pacific Lung Cancer Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Test
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Lung Cancer Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Test
- 6.3.2. India Lung Cancer Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Test
- 6.3.3. Australia Lung Cancer Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Test
- 6.3.4. Japan Lung Cancer Diagnostics Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Type
    - 6.3.4.2.2. By Test
- 6.3.5. South Korea Lung Cancer Diagnostics Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Type
    - 6.3.5.2.2. By Test

7. Europe Lung Cancer Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Test
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Lung Cancer Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Test
- 7.3.2. Germany Lung Cancer Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Test
- 7.3.3. Spain Lung Cancer Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Test
- 7.3.4. Italy Lung Cancer Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Test
- 7.3.5. United Kingdom Lung Cancer Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Test

8. North America Lung Cancer Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Test
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Lung Cancer Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Test
- 8.3.2. Mexico Lung Cancer Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Test
- 8.3.3. Canada Lung Cancer Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Test

9. South America Lung Cancer Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Test
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Lung Cancer Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Test
- 9.3.2. Argentina Lung Cancer Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Test
- 9.3.3. Colombia Lung Cancer Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Test

10. Middle East and Africa Lung Cancer Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Test
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Lung Cancer Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Test
- 10.3.2. Saudi Arabia Lung Cancer Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Test
- 10.3.3. UAE Lung Cancer Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Test
- 10.3.4. Egypt Lung Cancer Diagnostics Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Type
    - 10.3.4.2.2. By Test

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Lung Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Sanofi S.A.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (In case of listed)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
15.2. Roche Diagnostics Corporation
15.3. bioMerieux SA
15.4. Qiagen N.V.
15.5. Agilent Technologies, Inc.
15.6. Thermo Fisher Scientific Inc.
15.7. AstraZeneca plc
15.8. Illumina Inc.
15.9. Johnson & Johnson
15.10. Abbott Laboratories Inc

16. Strategic Recommendations

17. About Us & Disclaimer

02-2729-4219

+886-2-2729-4219

License/价格

肺癌诊断市场 - 全球产业规模、份额、趋势、机会和预测，按类型、地区和竞争测试划分，2019-2029F

Lung Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Test By Region and Competition, 2019-2029F

主要市场驱动因素

主要市场挑战

主要市场趋势

细分市场洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球肺癌诊断市场展望

第 6 章：亚太地区肺癌诊断市场展望

第 7 章：欧洲肺癌诊断市场展望

第 8 章：北美肺癌诊断市场展望

第 9 章：南美洲肺癌诊断市场展望

第 10 章：中东和非洲肺癌诊断市场展望

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球肺癌诊断市场：SWOT 分析

第 14 章：波特的五力分析

第15章：竞争格局

第 16 章：策略建议

第17章调查会社について・免责事项

Key Market Players

Report Scope:

Lung Cancer Diagnostics Market, By Type:

Lung Cancer Diagnostics Market, By Test:

Lung Cancer Diagnostics Market, By Region:

Competitive Landscape

Available Customizations:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Lung Cancer Diagnostics Market Outlook

6. Asia Pacific Lung Cancer Diagnostics Market Outlook

7. Europe Lung Cancer Diagnostics Market Outlook

8. North America Lung Cancer Diagnostics Market Outlook

9. South America Lung Cancer Diagnostics Market Outlook

10. Middle East and Africa Lung Cancer Diagnostics Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Global Lung Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

16. Strategic Recommendations

17. About Us & Disclaimer